Tags : 2018

AbbVie Terminates Tau and ASN Agreement with Voyager Signed in

Shots: Voyager retains full rights to the vectorization technology and novel vectorized Abs emerges from the collaboration and has the right to pursue vectorized Ab programs targeting tau and alpha-synuclein alone or in collaboration with another partner As per collaboration agreements, Voyager has received an upfront payment to perform research and preclinical development of vectorized […]Read More

Sanofi Expands its 2018 Collaboration with Translate Bio to Develop

Shots: Translate Bio to receive $425M up front consisting $300M in cash and $125M as equity investment at $25.59/ share representing a 50% premium to the 20-day moving average share price prior to signing. The company will receive ~$1.9B as milestones, including $450M milestones under the 2018 agreement and expects $360M in next few years […]Read More

Sierra Oncology Amends its Asset Purchase Agreement with Gilead for

Shots: As per the amended agreement, Gilead will reduce the royalty rates of Momelotinib & eliminates milestone payments in exchange for becoming a stockholder in Sierra, following the closing of Sierra’s qualified financing. In Aug’2018, Sierra acquired Gilead’s Momelotinib for $3M up front, $195M milestones and royalties on sales Additionally, Sierra and Gilead Sciences would […]Read More

Top 20 Biopharma Acquisitions of 2018 Based on the Total

Biopharma acquisition activity in 2018 shows a significant increase over the previous year. Takeda proved to be on top with the acquisition of Shire among the top 20 acquisitions with a total deal value of $57.17B strengthening its capabilities in gastroenterology, neuroscience, oncology, rare diseases, and plasma-derived therapies. This article is based on the 2018 […]Read More

Mylan to Make Amendments in its 2018 License Agreement with

Mylan to pay $5M up front in addition to $25M (according to 2018 deal), contingent payments ~$100M, ~$225M milestones on the achievement of specified clinical and regulatory milestones and royalties on sales of the biosimilar in Mylan territories The amendment is made in the extension of time for Mylan to develop and commercialize biosimilar of […]Read More

Top 20 Immunology Companies Based on 2018 Immunology Segment Revenue

The increasing cases of autoimmune disorders such as rheumatoid arthritis are driving the growth of immunology products in the global market. Multiple companies have been focusing on Oncology, Hematology and multiple diseases but due to a drastic increase in the immune disorders, Immunology segment has been widely spared across the globe. In the top 20 […]Read More

Top 20 Diagnostics Companies Based On 2018 Revenue

With the era of growing diseases, Diagnostics have played a vital role in diagnosing multiple diseases and disorders. The healthcare system is changing, with a greater focus on value, reducing errors and giving more cost-effective care and treatments. The Diagnostic ledger has not changed much in comparison to 2017. Roche Diagnostics holds to be at […]Read More

Insights+: An Analysis of Biopharma Companies Growth in Last 20

In the last 20 years the global Biopharma space has changed a lot with ups and downs of companies and their growth. This analysis has found the multiple acquisitions and mergers along with the launch of several blockbusters leading to jump in growth and revenue of numerous companies. Pfizer acquired Warner-Lambert in 2000 to gain […]Read More

Top 10 Oncology Companies By 2018 Revenue

The Pharma companies focusing on oncology has been emerging in market with greater needs of people suffering from Cancer. The sales of oncology drugs gradually increasing with diseases. The top oncology companies are now developing more advanced, effective, and tolerable drugs to improve treatment outcomes and the patient experience. Roche proved to be on top […]Read More